[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

LTC2932970I2 - Antivirusinė terapija - Google Patents

Antivirusinė terapija

Info

Publication number
LTC2932970I2
LTC2932970I2 LTPA2018013C LTPA2018013C LTC2932970I2 LT C2932970 I2 LTC2932970 I2 LT C2932970I2 LT PA2018013 C LTPA2018013 C LT PA2018013C LT PA2018013 C LTPA2018013 C LT PA2018013C LT C2932970 I2 LTC2932970 I2 LT C2932970I2
Authority
LT
Lithuania
Prior art keywords
antiviral therapy
antiviral
therapy
Prior art date
Application number
LTPA2018013C
Other languages
English (en)
Original Assignee
Viiv Healthcare Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44319704&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LTC2932970(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Viiv Healthcare Company filed Critical Viiv Healthcare Company
Publication of LTPA2018013I1 publication Critical patent/LTPA2018013I1/lt
Publication of LTC2932970I2 publication Critical patent/LTC2932970I2/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
LTPA2018013C 2010-01-27 2018-10-22 Antivirusinė terapija LTC2932970I2 (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29858910P 2010-01-27 2010-01-27
EP11737484.3A EP2531027B1 (en) 2010-01-27 2011-01-24 Therapeutic combination comprising dolutegravir, abacavir and lamivudine

Publications (2)

Publication Number Publication Date
LTPA2018013I1 LTPA2018013I1 (lt) 2018-11-12
LTC2932970I2 true LTC2932970I2 (lt) 2022-04-25

Family

ID=44319704

Family Applications (4)

Application Number Title Priority Date Filing Date
LTEP16187411.0T LT3127542T (lt) 2010-01-27 2011-01-24 Antivirusinė terapija
LTEP19151897.6T LT3494972T (lt) 2010-01-27 2011-01-24 Dolutegraviro ir lamivudino kompozicija živ infekcijai gydyti
LTEP15164931.6T LT2932970T (lt) 2010-01-27 2011-01-24 Antivirusinė terapija
LTPA2018013C LTC2932970I2 (lt) 2010-01-27 2018-10-22 Antivirusinė terapija

Family Applications Before (3)

Application Number Title Priority Date Filing Date
LTEP16187411.0T LT3127542T (lt) 2010-01-27 2011-01-24 Antivirusinė terapija
LTEP19151897.6T LT3494972T (lt) 2010-01-27 2011-01-24 Dolutegraviro ir lamivudino kompozicija živ infekcijai gydyti
LTEP15164931.6T LT2932970T (lt) 2010-01-27 2011-01-24 Antivirusinė terapija

Country Status (45)

Country Link
US (12) US20120295898A1 (lt)
EP (6) EP2932970B1 (lt)
JP (8) JP2013518107A (lt)
KR (4) KR101830715B1 (lt)
CN (2) CN102791129B (lt)
AP (1) AP3551A (lt)
AU (1) AU2011209788C1 (lt)
BR (1) BR112012018670A2 (lt)
CA (4) CA3003988C (lt)
CL (1) CL2012002080A1 (lt)
CO (1) CO6602152A2 (lt)
CR (1) CR20120423A (lt)
CY (4) CY1116509T1 (lt)
DK (4) DK2531027T3 (lt)
DO (2) DOP2012000205A (lt)
EA (4) EA032868B1 (lt)
EC (1) ECSP12012106A (lt)
ES (4) ES2543066T3 (lt)
FI (2) FI3494972T3 (lt)
FR (2) FR18C1043I2 (lt)
HK (3) HK1179522A1 (lt)
HR (4) HRP20240168T1 (lt)
HU (6) HUE040554T2 (lt)
IL (5) IL221007A (lt)
LT (4) LT3127542T (lt)
LU (1) LUC00090I2 (lt)
MA (1) MA34002B1 (lt)
ME (2) ME03058B (lt)
MX (4) MX367938B (lt)
MY (2) MY188334A (lt)
NO (2) NO2932970T3 (lt)
NZ (4) NZ627824A (lt)
PE (2) PE20121524A1 (lt)
PH (2) PH12016500195B1 (lt)
PL (4) PL3494972T3 (lt)
PT (4) PT2932970T (lt)
RS (4) RS54123B1 (lt)
SG (3) SG10201509476RA (lt)
SI (4) SI3127542T1 (lt)
SM (1) SMT201500177B (lt)
TN (1) TN2012000376A1 (lt)
TR (1) TR201807704T4 (lt)
UA (1) UA105556C2 (lt)
WO (1) WO2011094150A1 (lt)
ZA (1) ZA201205586B (lt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA105556C2 (uk) 2010-01-27 2014-05-26 Віів Гелскер Компані Комбінація сполук, що містить інгібітори віл інтегрази з іншими терапевтичними агентами
MX364901B (es) 2012-10-23 2019-05-10 Cipla Ltd Composicion farmaceutica antirretroviral.
TWI642669B (zh) 2012-12-21 2018-12-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
EP2767272A1 (en) * 2013-02-18 2014-08-20 Ratiopharm GmbH Solid pharmaceutical dosage form of dolutegravir
EP2956123A1 (en) 2013-02-18 2015-12-23 ratiopharm GmbH Solid pharmaceutical dosage form of dolutegravir
NO2865735T3 (lt) 2013-07-12 2018-07-21
SI3252058T1 (sl) 2013-07-12 2021-03-31 Gilead Sciences, Inc. Policiklične karbamoilpiridonske spojine in njihova uporaba za zdravljenje okužb s HIV
AU2014324829B2 (en) 2013-09-27 2017-09-07 Merck Sharp & Dohme Corp. Substituted Quinolizine Derivatives useful as HIV integrase inhibitors
IN2014MU00916A (lt) 2014-03-20 2015-09-25 Cipla Ltd
US10300074B2 (en) 2014-06-04 2019-05-28 Sanford Burnham Prebys Medical Discovery Institute Use of inhibitor of apoptosis protein (IAP) antagonists in HIV therapy
TWI744723B (zh) 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
NO2717902T3 (lt) 2014-06-20 2018-06-23
US10189860B2 (en) 2014-07-29 2019-01-29 Lek Pharmaceuticals D.D. Hydrates of dolutegravir sodium
TWI738321B (zh) 2014-12-23 2021-09-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
KR101982431B1 (ko) 2015-04-02 2019-05-27 길리애드 사이언시즈, 인코포레이티드 폴리시클릭-카르바모일피리돈 화합물 및 그의 제약 용도
WO2017029226A1 (en) 2015-08-14 2017-02-23 Sandoz Ag Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz
WO2017205585A1 (en) * 2016-05-27 2017-11-30 Viiv Healthcare Company Combinations and uses treatments thereof
WO2018028841A1 (en) * 2016-08-12 2018-02-15 Sandoz Ag Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz
WO2018042332A1 (en) * 2016-08-31 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Combinations and uses and treatments thereof
EP3655106A4 (en) * 2017-07-18 2021-04-21 VIIV Healthcare Company COMBINED INGREDIENTS THERAPY
EP3654980A1 (en) 2017-07-21 2020-05-27 VIIV Healthcare Company Regimens for treating hib infections and aids
JP2020528413A (ja) * 2017-07-21 2020-09-24 ヴィーブ ヘルスケア カンパニー Ｈｉｖ感染症及びａｉｄｓを治療するためのレジメン
MX2020003377A (es) * 2017-10-13 2020-09-28 Viiv Healthcare Co Formulacion de tableta farmaceutica de dos capas.
EP4122537A1 (en) 2019-03-22 2023-01-25 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
WO2021142150A1 (en) * 2020-01-09 2021-07-15 University Of Washington Long-acting therapeutic agent combinations and methods thereof
CN115151545A (zh) 2020-02-24 2022-10-04 吉利德科学公司 用于治疗hiv感染的四环化合物
DK4196479T3 (da) 2021-01-19 2024-01-22 Gilead Sciences Inc Substituerede pyridotriazinforbindelser og anvendelser deraf
AU2023225805A1 (en) * 2022-02-28 2024-10-17 Jericho Sciences, Llc Methods for viral infections
TWI843506B (zh) 2022-04-06 2024-05-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US7119202B1 (en) 1989-02-08 2006-10-10 Glaxo Wellcome Inc. Substituted-1,3-oxathiolanes and substituted-1,3-dioxolanes with antiviral properties
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
ZA923641B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9111902D0 (en) 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
GB9204015D0 (en) 1992-02-25 1992-04-08 Wellcome Found Therapeutic nucleosides
IL106507A (en) 1992-08-07 1997-11-20 Merck & Co Inc Pharmaceutical compositions containing benzoxazinones and some novel compounds of this type
US5663169A (en) 1992-08-07 1997-09-02 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
GB9402161D0 (en) 1994-02-04 1994-03-30 Wellcome Found Chloropyrimidine intermediates
IL113432A (en) 1994-04-23 2000-11-21 Glaxo Group Ltd Process for the diastereoselective synthesis of nucleoside analogues
UA49803C2 (uk) 1994-06-03 2002-10-15 Дж.Д. Сьорль Енд Ко Спосіб лікування ретровірусних інфекцій
MY115461A (en) 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US5849911A (en) 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
WO1997049411A1 (en) * 1996-06-25 1997-12-31 Glaxo Group Limited Combinations comprising vx478, zidovudine, ftc and/or 3tc for use in the treatment of hiv
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5965729A (en) 1997-02-05 1999-10-12 Merck & Co., Inc. Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent
GB9709945D0 (en) 1997-05-17 1997-07-09 Glaxo Group Ltd A novel salt
US5935946A (en) 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
GB9717928D0 (en) 1997-08-22 1997-10-29 Glaxo Group Ltd Process for the enatioselective hydrolysis of n-derivatised lactams
GB9721780D0 (en) 1997-10-14 1997-12-10 Glaxo Group Ltd Process for the synthesis of chloropurine intermediates
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
US6087383A (en) 1998-01-20 2000-07-11 Bristol-Myers Squibb Company Bisulfate salt of HIV protease inhibitor
GB9805898D0 (en) 1998-03-20 1998-05-13 Glaxo Group Ltd Process for the sythesis of hiv protease inhibitors
AU3366899A (en) 1998-03-27 1999-10-18 Regents Of The University Of California, The Novel hiv integrase inhibitors and hiv therapy based on drug combinations including integrase inhibitors
UA72207C2 (uk) 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення
GB9809213D0 (en) * 1998-04-29 1998-07-01 Glaxo Group Ltd Pharmaceutical compositions
GB9815567D0 (en) 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
EP1255510B3 (en) 2000-01-31 2009-03-04 Cook Biotech, Inc. Stent valves
EE05400B1 (et) 2001-04-10 2011-04-15 Pfizer Inc. Prasoolderivaadid, neid v?i nende farmatseutiliselt vastuv?etavaid sooli, solvaate v?i derivaate sisaldavad farmatseutilised kompositsioonid, nende kasutamine ning meetodid nende valmistamiseks
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
US7638522B2 (en) * 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
AR040242A1 (es) 2002-06-04 2005-03-23 Glaxo Group Ltd Composiciones farmaceuticas
US20060084627A1 (en) * 2002-06-27 2006-04-20 Medivir Ab Synergistic interaction of abacavir and alovudine
JP4996241B2 (ja) * 2003-01-14 2012-08-08 ギリアード サイエンシーズ， インコーポレイテッド 組み合わせ抗ウイルス治療のための組成物および方法
TW200510425A (en) 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
WO2005077050A2 (en) * 2004-02-11 2005-08-25 Smithkline Beecham Corporation Hiv integrase inhibitors
JP4285353B2 (ja) 2004-03-05 2009-06-24 清水建設株式会社 化学物質放散度評価方法
ATE411030T1 (de) * 2004-04-14 2008-10-15 Gilead Sciences Inc Phosphonatanaloga von hiv- integrasehemmerverbindungen
EP1758581A1 (en) 2004-05-21 2007-03-07 Japan Tobacco, Inc. Combinations comprising a 4-isoquinolone derivative and anti-hiv agents
US7176196B2 (en) 2004-05-28 2007-02-13 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
ATE495747T1 (de) 2004-08-23 2011-02-15 Teva Pharma Kristalline form des ibandronat-natriums und herstellungsverfahren dafür
WO2006024668A1 (en) 2004-09-02 2006-03-09 Janssen Pharmaceutica N.V. Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile
CN102304150B (zh) 2004-09-17 2014-06-18 埃迪尼克斯医药公司 作为hiv抑制剂的磷酸-吲哚
US7250421B2 (en) 2005-01-31 2007-07-31 University Of Georgia Research Foundation, Inc. Diketo acids with nucleobase scaffolds: anti-HIV replication inhibitors targeted at HIV integrase
WO2006096444A2 (en) 2005-03-04 2006-09-14 Smithkline Beecham Corporation Chemical compounds
UA96568C2 (en) * 2005-04-28 2011-11-25 Глаксосмиткляйн Ллк Polycyclic carbamoyl pyridone derivative as hiv-integrase inhibitor
PT3045206T (pt) 2005-04-28 2018-07-05 Shionogi & Co Derivado policíclico de carbamoilpiridona possuindo atividade inibidora de hiv-integrase
US20080280849A1 (en) 2005-06-01 2008-11-13 Herve Leh Synergic Combinations Comprising a Quinoline Compound and Other Hiv Infection Therapeutic Agents
CA2847871C (en) 2005-12-30 2016-07-26 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
UA108605C2 (uk) * 2005-12-30 2015-05-25 Спосіб покращення фармакокінетики інгібіторів інтегрази віл
SI1981506T1 (sl) * 2006-01-20 2013-08-30 Janssen R&D Ireland Dolgoročno zdravljenje infekcije HIV s TCM278
US20080039428A1 (en) 2006-06-29 2008-02-14 Panacos Pharmaceuticals, Inc. Antiretroviral combination therapy
US20090306112A1 (en) 2006-07-21 2009-12-10 Gilead Sciences, Inc. Antiviral protease inhibitors
EA016267B1 (ru) 2006-09-29 2012-03-30 Айденикс Фармасьютикалз, Инк. Энантиомерно чистые фосфоиндолы в качестве ингибиторов hiv
EP2487161B2 (en) 2007-02-23 2024-06-05 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
US20080241289A1 (en) 2007-02-23 2008-10-02 Auspex Pharmaceuticals, Inc. Preparation and utility of non-nucleoside reverse transcriptase inhibitors
MX2009013804A (es) 2007-06-29 2010-02-03 Korea Res Inst Chem Tech Inhibidores novedosos de transcriptasa inversa de vih.
US8354421B2 (en) 2007-06-29 2013-01-15 Korea Research Insitute Of Chemical Technology HIV reverse transcriptase inhibitors
KR20100040896A (ko) 2007-07-06 2010-04-21 길리애드 사이언시즈, 인코포레이티드 치료제의 약동학적 특성의 조절제
ES2437331T3 (es) * 2007-07-12 2014-01-10 Janssen R&D Ireland Forma cristalina de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]-2-pirimidinil]amino]benzonitrilo
WO2009058923A1 (en) 2007-10-31 2009-05-07 Smithkline Beecham Corporation Ccr5 antagonists as therapeutic agents
JP2011502998A (ja) 2007-11-01 2011-01-27 ザ ユーエイビー リサーチ ファウンデイション ウイルス感染の治療および予防
US8108055B2 (en) 2007-12-28 2012-01-31 Larry Wong Method, system and apparatus for controlling an electrical device
EP2250185A4 (en) * 2008-01-03 2011-11-16 Virochem Pharma Inc NEW LUPANDERIVATE
CN101977924A (zh) 2008-01-03 2011-02-16 Viro化学制药公司 新的c-21-酮基羽扇烷衍生物、其制备方法和应用
WO2009088719A1 (en) 2008-01-04 2009-07-16 Gilead Sciences, Inc. Inhibitors of cytochrome p450
EP2257567A1 (en) 2008-02-14 2010-12-08 Virochem Pharma Inc. Novel 17 beta lupane derivatives
WO2009148600A2 (en) * 2008-06-06 2009-12-10 Concert Pharmaceuticals, Inc. Deuterated lysine-based compounds
PL2320908T3 (pl) * 2008-07-25 2014-06-30 Viiv Healthcare Co Proleki dolutegrawiru
US8552187B2 (en) 2008-12-11 2013-10-08 Shionogi & Co., Ltd. Processes and intermediates for carbamoylpyridone HIV integrase inhibitors
KR101733625B1 (ko) 2008-12-11 2017-05-10 시오노기세야쿠 가부시키가이샤 카르바모일피리돈 ｈｉｖ 인테그라제 억제제 및 중간체의 합성
UA105556C2 (uk) 2010-01-27 2014-05-26 Віів Гелскер Компані Комбінація сполук, що містить інгібітори віл інтегрази з іншими терапевтичними агентами
GB201006038D0 (en) 2010-04-12 2010-05-26 Unilever Plc Improvements relating to antiviral compositions
JP2013541493A (ja) 2010-06-17 2013-11-14 フュジアンス バイオメディカルズ インコーポレイテッド 抗ウイルス剤として有用な化合物、組成物、及び使用の方法
CA2832066C (en) 2011-04-01 2023-04-18 The Medicines Company Short-acting dihydropyridines (clevidipine) for use in reducing stroke damage

Also Published As

Publication number Publication date
JP2023085431A (ja) 2023-06-20
EA201690872A2 (ru) 2016-08-31
SMT201500177B (it) 2015-09-07
EA201892277A1 (ru) 2019-03-29
EA201690872A3 (ru) 2016-12-30
MY188334A (en) 2021-11-30
EP3127542B1 (en) 2018-08-22
CY2018029I2 (el) 2019-07-10
HRP20240168T1 (hr) 2024-04-26
IL221007A (en) 2016-06-30
US20210401850A1 (en) 2021-12-30
IL281959A (en) 2021-05-31
NZ627826A (en) 2016-01-29
MX2012008774A (es) 2012-08-17
LT2932970T (lt) 2018-06-25
EA202190473A3 (ru) 2021-12-31
FIC20240016I1 (fi) 2024-05-31
HRP20181531T1 (hr) 2018-11-16
PL2531027T3 (pl) 2016-01-29
EP2531027B1 (en) 2015-05-06
JP2018127473A (ja) 2018-08-16
KR101964923B1 (ko) 2019-04-02
JP2022071126A (ja) 2022-05-13
MA34002B1 (fr) 2013-02-01
HUS1800042I1 (hu) 2018-11-28
KR101830715B1 (ko) 2018-04-04
JP2021091705A (ja) 2021-06-17
US20170281636A1 (en) 2017-10-05
HUE037812T2 (hu) 2018-09-28
PE20160180A1 (es) 2016-05-04
ZA201205586B (en) 2014-01-29
PH12016500195A1 (en) 2016-12-05
ES2969969T3 (es) 2024-05-23
LUC00090I2 (lt) 2019-01-08
CY1116509T1 (el) 2017-03-15
KR101883750B1 (ko) 2018-07-31
IL245182A0 (en) 2016-06-30
EP3127542A1 (en) 2017-02-08
PT2531027E (pt) 2015-09-16
KR20120128640A (ko) 2012-11-27
JP2013518107A (ja) 2013-05-20
RS57728B1 (sr) 2018-12-31
DOP2021000147A (es) 2022-01-16
US20180200254A1 (en) 2018-07-19
PT2932970T (pt) 2018-06-08
FR18C1043I2 (fr) 2019-10-11
FI3494972T3 (fi) 2024-03-01
ES2670811T3 (es) 2018-06-01
HUE065569T2 (hu) 2024-06-28
HUE040554T2 (hu) 2019-03-28
SI3127542T1 (sl) 2018-11-30
JP2016145204A (ja) 2016-08-12
PH12016500195B1 (en) 2016-12-05
EA202190473A2 (ru) 2021-06-30
AP2012006445A0 (en) 2012-08-31
IL257267A (en) 2018-03-29
NO2018036I1 (no) 2018-10-15
CN102791129A (zh) 2012-11-21
MX356891B (es) 2018-06-19
HUE026849T2 (en) 2016-08-29
PL3127542T3 (pl) 2019-03-29
US20200230147A1 (en) 2020-07-23
US20160339033A1 (en) 2016-11-24
RS54123B1 (en) 2015-12-31
HRP20180855T1 (hr) 2018-06-29
CA2967453C (en) 2018-07-17
MX367938B (es) 2019-09-12
AP3551A (en) 2016-01-18
IL281959B (en) 2021-12-01
EA201290583A1 (ru) 2013-04-30
US10426780B2 (en) 2019-10-01
TR201807704T4 (tr) 2018-06-21
PH12018502489A1 (en) 2020-06-15
PT3494972T (pt) 2024-02-12
EP3351249A1 (en) 2018-07-25
ES2688925T3 (es) 2018-11-07
IL245182B (en) 2018-04-30
US20170119777A1 (en) 2017-05-04
NZ627827A (en) 2016-02-26
CA3003988A1 (en) 2011-08-04
EP4316599A2 (en) 2024-02-07
PL2932970T3 (pl) 2018-08-31
JP6268386B2 (ja) 2018-01-31
AU2011209788B2 (en) 2014-02-06
JP2019167371A (ja) 2019-10-03
EP2531027A1 (en) 2012-12-12
CA2787691A1 (en) 2011-08-04
EP2932970A1 (en) 2015-10-21
RS57323B1 (sr) 2018-08-31
SG182614A1 (en) 2012-08-30
CA3060290A1 (en) 2011-08-04
US20160199379A1 (en) 2016-07-14
EP3494972B1 (en) 2023-12-13
KR20160111536A (ko) 2016-09-26
RS65183B1 (sr) 2024-03-29
JP2017008087A (ja) 2017-01-12
LT3127542T (lt) 2018-11-26
ECSP12012106A (es) 2013-05-31
FR24C1024I1 (fr) 2024-07-26
IL257267B (en) 2019-08-29
MY202778A (en) 2024-05-21
NZ601319A (en) 2014-08-29
IL221007A0 (en) 2012-09-24
WO2011094150A1 (en) 2011-08-04
EP2531027A4 (en) 2013-07-03
CL2012002080A1 (es) 2012-11-30
CN105311033B (zh) 2019-05-07
SI3494972T1 (sl) 2024-03-29
CO6602152A2 (es) 2013-01-18
CN102791129B (zh) 2015-09-30
SG10201509476RA (en) 2015-12-30
PL3494972T3 (pl) 2024-05-27
IL267658B (en) 2021-04-29
NO2932970T3 (lt) 2018-08-18
US20170216284A1 (en) 2017-08-03
CR20120423A (es) 2012-11-22
US20120295898A1 (en) 2012-11-22
HK1250335A1 (zh) 2018-12-14
US20170079982A1 (en) 2017-03-23
ME03058B (me) 2019-01-20
CN105311033A (zh) 2016-02-10
CA2787691C (en) 2018-07-17
UA105556C2 (uk) 2014-05-26
MX367937B (es) 2019-09-12
EA025176B1 (ru) 2016-11-30
EP2932970B1 (en) 2018-03-21
CY1121040T1 (el) 2019-12-11
PE20121524A1 (es) 2012-12-03
SI2932970T1 (en) 2018-07-31
EA037601B1 (ru) 2021-04-20
CY2018029I1 (el) 2019-07-10
SG10201707183TA (en) 2017-10-30
IL267658A (en) 2019-08-29
EP3494972A1 (en) 2019-06-12
KR20170078868A (ko) 2017-07-07
US20150238496A1 (en) 2015-08-27
EA032868B1 (ru) 2019-07-31
LTPA2018013I1 (lt) 2018-11-12
DOP2012000205A (es) 2012-10-15
CA2967453A1 (en) 2011-08-04
TN2012000376A1 (en) 2014-01-30
NZ627824A (en) 2016-02-26
DK2531027T3 (en) 2015-07-20
ME02182B (me) 2015-10-20
SI2531027T1 (sl) 2015-08-31
US20180098992A1 (en) 2018-04-12
HUS2400017I1 (hu) 2024-06-28
DK2932970T3 (en) 2018-05-28
DK3127542T3 (en) 2018-11-12
BR112012018670A2 (pt) 2018-02-06
ES2543066T3 (es) 2015-08-14
HRP20150770T1 (hr) 2015-08-28
DK3494972T3 (da) 2024-01-29
CA3060290C (en) 2022-07-12
PT3127542T (pt) 2018-11-26
EP4316599A3 (en) 2024-04-10
HK1209629A1 (en) 2016-04-08
AU2011209788C1 (en) 2014-08-28
FR18C1043I1 (lt) 2018-11-30
AU2011209788A1 (en) 2012-08-16
CY1120457T1 (el) 2019-07-10
US11234985B2 (en) 2022-02-01
CA3003988C (en) 2020-01-07
KR20180078358A (ko) 2018-07-09
HK1179522A1 (en) 2013-10-04
LT3494972T (lt) 2024-03-12

Similar Documents

Publication Publication Date Title
LTC2932970I2 (lt) Antivirusinė terapija
SMT201600400B (it) Inalatore
BR112013013026A2 (pt) inalador
BR112013033974A2 (pt) terapia de combinação
DK2760886T3 (da) Immunocytokin-kombinationsterapi
FI20115876A0 (fi) Yhdistelmähoito
BR112012027133A2 (pt) inalador
FI20115640A0 (fi) Yhdistelmähoito
DK2663304T3 (da) Kombinationsterapi
UA20316S (uk) Манекен - торс чоловічий
UA20314S (uk) Манекен - торс жіночий
UA20315S (uk) Манекен - торс жіночий
UA20603S (uk) Манекен - торс жіночий
FIU20100101U0 (fi) Kiinnitysosa
ES1075603Y (es) Objeto terapeutico
DK2593113T3 (da) Celleterapi
ITNU20100010U1 (it) Massaggiatore infradito
DK2380545T3 (da) Terapi-indretning
DOS2011000168S (es) Inhalador
FI9065U1 (fi) Teline